Gentle Bio-Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 12 Year,
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.87 M
- Satisfied Charges ₹ 4.50 M
- Revenue Growth 12.06%
- Profit Growth -94.47%
- Ebitda -76.85%
- Net Worth 1.01%
- Total Assets -15.42%
About Gentle Bio-Sciences
Gentle Bio-Sciences Private Limited (GBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 31 January 2013 and has a history of 12 years. Its registered office is in Medak, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹3.87 M. The company has closed loans amounting to ₹4.50 M, as per Ministry of Corporate Affairs (MCA) records.
Meka Murty, Nagavenkata Gutta, and Venkata Nukavarapu serve as directors at the Company.
Company Details
-
Location
Medak, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100TG2013PTC085539
-
Company No.
085539
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Jan 2013
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Gentle Bio-Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagavenkata Gutta
|
Managing Director | 17-May-2014 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Meka Murty
|
Director | 25-Mar-2013 | Current |
|
Venkata Nukavarapu
|
Director | 29-Oct-2018 | Current |
Financial Performance of Gentle Bio-Sciences.
Gentle Bio-Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.06% increase. The company also saw a substantial fall in profitability, with a 94.47% decrease in profit. The company's net worth moved up by a moderate rise of 1.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gentle Bio-Sciences?
In 2023, Gentle Bio-Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.87 M
₹4.50 M
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.39 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Oct 2021 | Axis Bank Limited | ₹3.87 M | Open |
| 03 Aug 2020 | Axis Bank Limited | ₹3.50 M | Satisfied |
| 05 Jan 2017 | Axis Bank Limited | ₹1.00 M | Satisfied |
How Many Employees Work at Gentle Bio-Sciences?
Unlock and access historical data on people associated with Gentle Bio-Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gentle Bio-Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gentle Bio-Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
